Top 10 Pharma Drug Discovery and Delivery Capital Raises in the U.S. – June 1st to 15th, 2025
Several interesting transactions closed in the Pharma Drug Discovery and Delivery sector over the past two weeks. If you would like more info or would like to discuss the capital raising market for your company, please contact me.
PE Growth/Expansion
- Alantos Pharmaceuticals Holding, drugs intended for the treatment of diabetes and inflammatory diseases, received development capital from Industrial Innovation Partners in June 2025.
- Paratek Pharmaceuticals, antibacterial products intended to treat infectious diseases and improve patient outcomes, received development capital from REPAIR Impact Fund in June 2025.
Merger/Acquisition
- Autumn DNA, supplement packs intended to offer a smart and easy path to optimized wellness, was acquired by DirectMeds on June 4, 2025.
- Focal Medical, novel drug delivery systems created for cancers that are difficult to treat with systemic therapy alone, was acquired by Continuity Biosciences on June 4, 2025.
Later Stage VC
- Allay Therapeutics, analgesic products designed to provide post-surgical pain management and recuperation for patients and physicians, raised $57.5 million of Series D venture funding in a deal led by Lightstone Ventures and ClavystBio on June 5, 2025, putting the company’s pre-money valuation at $68.5 million.
- Rebel Medicine, preclinical-stage life sciences company intended for leveraging innovative drug delivery science to transform how therapeutics are delivered, raised $6.07 million of Series A venture funding in a deal led by Crocker Ventures on June 12, 2025.
Early Stage VC
- Continuity Biosciences, advanced drug delivery technologies designed for treating complex diseases, raised $1 million of venture funding from investors on June 4, 2025.
- Emervax, mRNA-based vaccine platform designed for viral infectious diseases, including those that have the highest potential to cause epidemics and pandemics, raised an estimated $2.2 million of venture funding from Coalition for Epidemic Preparedness Innovations in June 2025.
Seed Round
- Conexeu Sciences, developer of regenerative aesthetics and wound care therapies intended to accelerate wound healing and enhance tissue regeneration, raised $1.29 million of seed funding investors on June 13, 2025.
- Gateway Biotechnology, developer of small-molecule therapeutics designed to treat patients having hearing disability, raised $633,000 of seed funding in the form of SAFE notes from investors on June 5, 2025.
#castleplacement #capitalraising #privateequity #venturecapital #investment #pharmaceuticals #biotechnology #pharmadrugdiscovery #pharmadrugdelivery
Please contact me if you have any questions or would like to discuss your capital raise:
Email: druddy@castleplacement.com
(C) (406) 868-3218
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement™ does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
